The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -154,258 |
| Stock-based compensation | 140,403 |
| Prepaid expenses | 10 |
| Other assets | -9,851 |
| Accounts payable | 521 |
| Accrued expenses | 1,231 |
| Net cash used in operating activities | -2,262 |
| Business combination | 26 |
| Proceeds from related party loans | 9,911 |
| Payments of deferred offering costs | 7,602 |
| Net cash (used in) provided by financing activities | 2,335 |
| Net change in cash and cash equivalents | 73 |
| Cash and cash equivalents at beginning of period | 12 |
| Cash and cash equivalents at end of period | 85 |
Semnur Pharmaceuticals, Inc. (SMNR)
Semnur Pharmaceuticals, Inc. (SMNR)